The estimated Net Worth of William L. Ostrander is at least $309 Thousand dollars as of 13 August 2020. Mr Ostrander owns over 15,625 units of Heat Biologics Inc stock worth over $37,188 and over the last 5 years he sold HTBX stock worth over $0. In addition, he makes $271,921 as CFO & Sec. at Heat Biologics Inc.
Mr has made over 1 trades of the Heat Biologics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 15,625 units of HTBX stock worth $8,125 on 13 August 2020.
The largest trade he's ever made was exercising 15,625 units of Heat Biologics Inc stock on 13 August 2020 worth over $8,125. On average, Mr trades about 3,125 units every 0 days since 2019. As of 13 August 2020 he still owns at least 15,625 units of Heat Biologics Inc stock.
You can see the complete history of Mr Ostrander stock trades at the bottom of the page.
William L. Ostrander is the CFO & Sec. at Heat Biologics Inc.
As the CFO & Sec. of Heat Biologics Inc, the total compensation of Mr Ostrander at Heat Biologics Inc is $271,921. There are 2 executives at Heat Biologics Inc getting paid more, with Jeffrey Alan Wolf having the highest compensation of $1,160,609.
Mr Ostrander is 53, he's been the CFO & Sec. of Heat Biologics Inc since . There are 4 older and no younger executives at Heat Biologics Inc. The oldest executive at Heat Biologics Inc is Dr. Anthony M. Manning Ph.D., 59, who is the Chief Scientific Advisor.
William's mailing address filed with the SEC is C/O HEAT BIOLOGICS, INC., 627 DAVIS DRIVE, SUITE 400, MORRISVILLE, NC, 27560.
Over the last 11 years, insiders at Heat Biologics Inc have traded over $311,853 worth of Heat Biologics Inc stock and bought 1,805,692 units worth $1,373,576 . The most active insiders traders include Louis C Bock, Michael Kharitonov, and John K A Prendergast. On average, Heat Biologics Inc executives and independent directors trade stock every 319 days with the average trade being worth of $582,988. The most recent stock trade was executed by John K A Prendergast on 14 May 2021, trading 35,000 units of HTBX stock currently worth $205,450.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Heat Biologics Inc executives and other stock owners filed with the SEC include: